HomeCompareACUR vs PLD

ACUR vs PLD: Dividend Comparison 2026

ACUR yields 20000.00% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ACUR wins by $52481917574412746752.00M in total portfolio value
10 years
ACUR
ACUR
● Live price
20000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$52481917574412746752.00M
Annual income
$51,970,745,957,167,775,000,000,000.00
Full ACUR calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — ACUR vs PLD

📍 ACUR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodACURPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ACUR + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ACUR pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ACUR
Annual income on $10K today (after 15% tax)
$1,700,000.00/yr
After 10yr DRIP, annual income (after tax)
$44,175,134,063,592,610,000,000,000.00/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, ACUR beats the other by $44,175,134,063,592,610,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ACUR + PLD for your $10,000?

ACUR: 50%PLD: 50%
100% PLD50/50100% ACUR
Portfolio after 10yr
$26240958787206373376.00M
Annual income
$25,985,372,978,583,888,000,000,000.00/yr
Blended yield
99.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

ACUR
Analyst Ratings
3
Buy
Consensus: Buy
Altman Z
-635.4
Piotroski
2/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ACUR buys
0
PLD buys
0
No recent congressional trades found for ACUR or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricACURPLD
Forward yield20000.00%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$52481917574412746752.00M$6.50M
Annual income after 10y$51,970,745,957,167,775,000,000,000.00$5,256,436.18
Total dividends collected$52448189483771600896.00M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: ACUR vs PLD ($10,000, DRIP)

YearACUR PortfolioACUR Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$2,010,700$2,000,000.00$11,255$555.24+$2.00MACUR
2$377,983,225$375,831,775.70$13,062$1,018.59+$377.97MACUR
3$66,433,479,469$66,029,037,418.28$15,903$1,926.67+$66433.46MACUR
4$10,916,985,471,987$10,845,901,648,955.73$20,839$3,823.32+$10916985.45MACUR
5$1,677,384,363,769,318$1,665,703,189,314,291.80$30,464$8,166.08+$1677384363.74MACUR
6$240,985,175,079,139,100$239,190,373,809,905,920.00$52,054$19,457.30+$240985175079.09MACUR
7$32,373,573,631,143,694,000$32,115,719,493,809,017,000.00$109,886$54,188.93+$32373573631143.58MACUR
8$4,066,766,648,320,630,000,000$4,032,126,924,535,306,000,000.00$304,030$186,451.18+$4066766648320629.50MACUR
9$477,730,483,406,513,300,000,000$473,379,043,092,810,300,000,000.00$1,166,125$840,813.32+$477730483406513344.00MACUR
10$52,481,917,574,412,750,000,000,000$51,970,745,957,167,775,000,000,000.00$6,504,190$5,256,436.18+$52481917574412746752.00MACUR

ACUR vs PLD: Complete Analysis 2026

ACURStock

Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was incorporated in 1935 and is based in Palatine, Illinois.

Full ACUR Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this ACUR vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ACUR vs SCHDACUR vs JEPIACUR vs OACUR vs KOACUR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.